Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies that modulate cellular protein levels. Leveraging their proprietary drug discovery platform, DELigase, Nurix focuses on a novel approach to target E3 ubiquitin ligases within the ubiquitin-proteasome system (UPS). This system regulates protein stabilization and degradation, providing therapeutic opportunities across various disease areas.
Founded by experts in the UPS field and initially funded by leading investors such as Third Rock Ventures and The Column Group, Nurix has positioned itself as a leader in developing first-in-class therapies. The company’s pipeline includes drug candidates that target protein degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). Their lead product candidate, NX-2127, is an orally available BTK degrader designed to treat relapsed or refractory B-cell malignancies. Another key candidate, NX-1607, is an orally available CBL-B inhibitor aimed at immuno-oncology indications.
Partnering with industry giants like Celgene, Sanofi, Gilead, and Pfizer, Nurix continues to expand its reach and capabilities. One significant collaboration with Sanofi targets the STAT6 pathway, a critical player in type 2 inflammation. The extension of this collaboration underscores the success and productivity of their ongoing research efforts. Nurix’s innovative approach is also evident in their BTK degrader NX-5948, demonstrating promising clinical activity in patients with CNS involvement.
In its recent financial update, Nurix reported strong results for the first quarter of 2024, with increased revenue driven by collaborations and research milestones. Despite reporting a net loss, the company holds substantial cash reserves to support ongoing and future projects. Leadership transitions within Nurix, such as the appointment of Julia P. Gregory as the new board chair, reflect the company’s commitment to strategic growth and innovation.
Headquartered in San Francisco, California, Nurix remains at the forefront of drug discovery and development, aiming to bring transformative therapies to patients with cancer, inflammatory conditions, and other challenging diseases. For more information, visit http://www.nurixtx.com.
Nurix Therapeutics (NRIX) has received FDA Fast Track designation for NX-5948, its selective BTK degrader, for treating relapsed/refractory Waldenstrom's macroglobulinemia patients who have undergone at least two prior therapies, including a BTK inhibitor. This designation follows positive Phase 1 clinical trial data and adds to the drug's existing Fast Track designation for CLL/SLL treatment received in January 2024. NX-5948 also received EMA PRIME designation in November 2024 for treating CLL/SLL. The company continues patient enrollment in the Phase 1b expansion cohort, with additional clinical data expected in 2025.
Nurix Therapeutics (NRIX) presented positive Phase 1a/1b clinical trial data for NX-5948 in treating chronic lymphocytic leukemia. The trial showed a 75.5% Objective Response Rate, increasing to 84.2% in patients with at least two disease assessments. The study included 60 heavily pretreated patients who received a median of four prior therapies.
The drug demonstrated effectiveness in patients with mutations associated with poor prognosis and BTK inhibitor resistance, including those with CNS involvement. NX-5948 showed a favorable safety profile across all doses tested, with common side effects including purpura/contusion, fatigue, and neutropenia. Responses were durable, with thirteen patients showing response beyond six months and five patients maintaining response past one year of treatment.
Nurix Therapeutics (NRIX) announced a webcast scheduled for December 9, 2024, at 8:15 p.m. PT to present new clinical data from its ongoing Phase 1a/1b trial of BTK degrader NX-5948. The presentation will feature Dr. Nirav N. Shah from the Medical College of Wisconsin, who will discuss trial results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Company executives will outline the clinical development strategy for NX-5948 in both oncology and autoimmune indications, along with updates on other clinical stage programs.
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Arthur T. Sands, M.D., Ph.D., president and CEO, will deliver a corporate update on December 3, 2024, at 2:30 p.m. ET in New York City. The presentation will be available via live webcast through the company's website, with the recording accessible for 30 days following the event.
Nurix Therapeutics (NRIX) has received PRIME designation from the European Medicines Agency for NX-5948, its selective BTK degrader, for treating relapsed or refractory chronic lymphocytic leukemia patients who have previously received BTK and BCL-2 inhibitor therapy. The PRIME designation, which provides enhanced support for promising medicines addressing unmet medical needs, was granted based on encouraging safety and efficacy data from ongoing Phase 1 trials. NX-5948 has shown potential activity against mutations resistant to current BTK inhibitors, with pivotal trials planned for 2025.
Nurix Therapeutics (NRIX) presented preclinical data for two autoimmune and inflammatory disease programs at ACR Convergence 2024. The first program, NX-5948, is an oral BTK degrader showing potential superiority over kinase inhibitors in inflammatory diseases. The second program, GS-6791, developed with Gilead Sciences, is an IRAK4 degrader for rheumatoid arthritis treatment.
Both compounds demonstrated strong efficacy in preclinical models. NX-5948 showed superior results in arthritis models and other inflammatory conditions, while GS-6791 exhibited robust dose-dependent efficacy in arthritis models with better cytokine response reduction compared to IRAK4 kinase inhibitors.
Nurix Therapeutics announced upcoming presentations of data from its BTK degrader programs, NX-5948 and NX-2127, at the 66th ASH Annual Meeting in December 2024. The presentations include two oral sessions and one poster presentation. The first oral presentation will discuss efficacy and safety results from an ongoing Phase 1a/b study of NX-5948 in relapsed/refractory CLL patients. The second oral presentation will focus on how NX-2127 and NX-5948 affect T cell functionality in CLL. Additionally, a poster presentation will showcase studies on BTK degradation as a therapeutic strategy for relapsed CNS lymphoma.
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in five major investor conferences in November 2024. The company's leadership team, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will attend:
- Truist BioPharma Symposium (NY, Nov 7)
- UBS Healthcare Conference (CA, Nov 12)
- Stephens Biotechnology Virtual Fireside Chats (Nov 14)
- Stifel Healthcare Conference (NY, Nov 18)
- Jefferies London Healthcare Conference (UK, Nov 21)
Webcasts for the UBS, Stifel, and Jefferies conferences will be available on Nurix's website for 30 days post-event.
Nurix Therapeutics (Nasdaq: NRIX) announced presentations at the 7th Annual TPD & Induced Proximity Summit, October 28-31, 2024, in Boston. The company will present new preclinical data on a brain-penetrant, pan-mutant B-Raf degrader and recent clinical data from the NX-5948 BTK degrader program.
Key presentations include:
- An orally bioavailable, brain-penetrant pan-mutant B-RAF degrader showing potent anti-tumor activity in multiple disease models
- Clinical activity of NX-5948 in CLL & NHL, demonstrating utility in relapsed/refractory B-cell malignancies, including cases with CNS involvement and BTK inhibitor resistance mutations
Nurix executives will also participate in panel discussions on strategic partnerships and the future of targeted protein degradation. The company aims to showcase its leadership in the field and the therapeutic potential of its targeted protein modulation approach.
Nurix Therapeutics presented positive results from its ongoing Phase 1a/1b clinical trial of NX-5948, an oral BTK degrader, in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) at the 12th International Workshop on Waldenstrom's Macroglobulinemia. Key findings include:
- 77.8% objective response rate (7 of 9 evaluable patients)
- Durable responses deepening over time
- Two patients on treatment for over a year
- Tolerable safety profile consistent with overall population
- Responses observed regardless of MYD88 and CXCR4 mutation status
The trial included heavily pretreated patients with a median of 3 prior lines of therapy. These results support the advancement of NX-5948 into the ongoing Phase 1b expansion cohort, including patients previously treated with BTK inhibitors and those with Bing-Neel syndrome.
FAQ
What is the current stock price of Nurix Therapeutics (NRIX)?
What is the market cap of Nurix Therapeutics (NRIX)?
What does Nurix Therapeutics, Inc. specialize in?
What is the significance of Nurix's DELigase platform?
Who are Nurix's major partners?
What are some of Nurix's key drug candidates?
How has Nurix performed financially in recent quarters?
Where is Nurix Therapeutics headquartered?
What recent leadership changes have occurred at Nurix?
What is the focus of Nurix's collaboration with Sanofi?
What are Nurix's plans for NX-5948?
How can I learn more about Nurix Therapeutics?
